HDAC9 and ovarian cancer: In a different study, the HDAC inhibitor belinostat was administered to platinum-resistant ovarian cancers, but similarly caused severe adverse events such as neutropenia, thrombocytopenia, and vomiting, leading to the termination of the study with no therapeutic benefit over standard treatment [43].